GlassScriptPhysician profile
Chang B Son
NPI 1063493898
$76,574.64
in general payments reported to CMS, 2019-2025
38 companies · $28K in 2025
The $28K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $248 · 2020: $1,453 · 2021: $80.93 · 2022: $1,520 · 2023: $27K · 2024: $18K · 2025: $28K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $63K · Food and Beverage: $7,649 · Consulting Fee: $2,902 · Travel and Lodging: $36.03.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62,686.25 |
| Food and Beverage | $7,648.54 |
| Consulting Fee | $2,902.00 |
| Travel and Lodging | $36.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $43,722.24 | 2021-2025 | Otezla, Otezla, Krystexxa |
| Incyte Corporation | $18,771.29 | 2022-2025 | Opzelura, Opzelura |
| E.R. Squibb & Sons, L.L.C. | $6,284.08 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $2,729.56 | 2022-2023 | Xeomin |
| Epi Health, LLC | $1,268.01 | 2019-2022 | |
| Dermavant Sciences, INC. | $563.15 | 2022-2024 | Vtama |
| Verrica Pharmaceuticals INC. | $553.43 | 2023-2024 | Ycanth |
| Arcutis Biotherapeutics, INC. | $396.50 | 2023-2025 | Zoryve |
| Pfizer INC. | $312.75 | 2021-2025 | |
| Leo Pharma INC. | $274.74 | 2019-2025 | Adbry, Anzupgo |
| Abbvie INC. | $248.32 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $219.23 | 2024-2025 | |
| Organon LLC | $129.97 | 2025 | Vtama, Nexplanon |
| Janssen Pharmaceuticals, INC | $124.99 | 2019 | |
| Genzyme Corporation | $122.28 | 2022-2025 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chang Son listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.